Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Relapsed acute myeloid leukemia: why is there no standard of care?.Best Pract Res Clin Haematol. 2013; 26: 253-259
- The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse.Leukemia. 2012; 26: 1313-1320
- Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.J Clin Oncol. 2012; 30: 3625-3632
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.Blood. 2012; 120: 1581-1588
- Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia.Am J Clin Pathol. 2016; 145: 769-777
- Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.Blood. 2012; 119: 332-341
- Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.Blood. 2000; 96: 3948-3952
- Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.Blood. 2004; 104: 3078-3085
- Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.Blood. 2003; 101: 3398-3406
- Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.Blood. 1997; 90: 2465-2470
- MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.Leukemia. 2004; 18: 1380-1390
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.Blood. 2001; 98: 1746-1751
- The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.Leukemia. 2006; 20: 1783-1789
- Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.J Clin Oncol. 2013; 31: 4123-4131
- Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.Cancer. 2017; 123: 426-435
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.Blood. 2013; 122: 1813-1821
- Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.J Clin Oncol. 2011; 29: 1190-1197
- Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.Best Pract Res Clin Haematol. 2013; 26: 279-284
- Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Haematologica. 2017; 102: 110-117
- Monitoring of minimal residual disease in acute myeloid leukemia.Cancer. 2008; 112: 4-16
- The role of multiparameter flow cytometry for disease monitoring in AML.Best Pract Res Clin Haematol. 2010; 23: 379-390
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).Blood. 2001; 97: 3574-3580
- Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.Cytometry B Clin Cytom. 2004; 62: 25-38
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease.Cytometry B Clin Cytom. 2014; 86: 3-14
- Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents.J Clin Pathol. 2016; 69: 1001-1008
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Blood. 2012; 120: 4840-4845
- Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.Leukemia. 2007; 21: 1700-1707
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.Nature. 2012; 481: 506-510
- Acute myeloid leukaemia in the elderly: a review.Br J Haematol. 2011; 152: 524-542
- Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.Ann Hematol. 1991; 63: 179-188
- Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.Blood. 2010; 116: 2224-2228
- Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.Blood. 2006; 108: 685-696
- AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance.Blood. 2009; 114: 2869-2877
- Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.J Clin Oncol. 2009; 27: 5580-5586
- Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.Best Pract Res Clin Haematol. 2014; 27: 229-234
- Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye.Cancer Cell. 2011; 19: 9-10
- The role of hypomethylating agents in the treatment of elderly patients with AML.J Geriatr Oncol. 2014; 5: 89-105
Article info
Publication history
Published online: September 26, 2017
Footnotes
The authors have nothing to disclose.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
